Societe Generale has downgraded Alcon (ALC) to hold from buy as the eye care companys immunity to macro headwinds is declining.
-- Plan to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022; Topline Data Expected in 1Q 2024 -- -- Received $60M Upfront Payment from Sale of EYSUVIS® and INVELTYS® to Alcon Inc. and Significantly Reduced Operating Expenses, Extending Cash Runway into 2Q 2024 -- -- Conference Call and Webcast at 8:00 a.m. ET -- ARLINGTON, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.
NEW YORK - Stocks that traded heavily or had substantial price changes Wednesday: Alcon Inc., down $3.53 to $71.94. The eye care company trimmed its profit and revenue…
Stocks that traded heavily or had substantial price changes Wednesday: Axon, Trade Desk rise; Alcon, Rackspace fall
Alcon Inc. (NYSE:ALC) traded at $72.00 at close of the session on Wednesday, August 10, made a downward move of -4.60% on its previous day’s price. Looking at the stock we see that its previous close was $75.47 and the beta (5Y monthly) reads 0.62 with the day’s price range being $75.35 – $76.06. The … Why Is Alcon Inc. (NYSE: ALC) Falling? Read More »
Alcon Inc. (NYSE:NYSE:ALC) Q2 2022 Results Conference Call August 10, 2022 08:00 AM ET Company Participants Dan Cravens - VP and Global Head IR David Endicott - CEO Tim Stonesifer - CFO…
Alcon (NYSE: ALC ) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here''s what investors need to know about the announcement. Earnings Alcon beat estimated earnings by 28.57%, reporting an EPS of $0.63 versus an estimate of $0.49. Revenue was up $106.00 million from the same period last … Full story available on Benzinga.com
Alcon press release (ALC): Q2 Non-GAAP EPS of $0.63 beats by $0.07.Revenue of $2.2B (+5.3% Y/Y) in-line.FY22 Guidance:Net Sales of $8.6B-$8.8B from prior outlook of $8.7 to $8.9…
GENEVA--(BUSINESS WIRE)--Alcon Reports Second Quarter 2022 Results
Howdy markets people. Phil Rosen here in Los Angeles. Officially, I''m a senior reporter, but I''m tempted to change my title to "Bear Whisperer" because that''s really what I spend much of my time doing lately. I''ve been reading bleak market forecasts and talking to pessimistic analysts at a higher clip than usual, and I''ve really honed an eye for bears. Today I''m breaking down what two top banks expect to happen on the Street in the coming months — one of which doesn''t see the bear market ending soon. If this was forwarded to you, sign up here . Download Insider''s app here. 1. It''s too premature to call the end to the stock downturn, according to Morgan Stanley. Inflation may have peaked, but that doesn''t mean equities are going to see any relief , analysts wrote in a Monday note. Companies are faced with the two-pronged challenge of falling prices and high labor costs, which weighs on profits and sets a trap for investors. "The rally in stocks has been powerful , and has many investors believing the bear market is over ," Morgan Stanley analysts said.
Alcon (NYSE: ALC ) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here''s what investors need to know before the announcement. Analysts estimate that Alcon will report an earnings per share (EPS) of $0.49. Alcon bulls will hope to hear the company to announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the … Full story available on Benzinga.com
Equity markets were churned by the July US jobs report on Friday, first falling sharply as treasury yields jolted higher on the day, but later rallying back to close the day only modestly lower. The US yield curve is about 10 basis points from its most dramatic inversion since 1982 as the market eyes an incoming recession despite the strong US jobs data and July ISM Services data last week. This week’s chief data focus is the Wednesday US July CPI data release. What is our trading focus? Nasdaq 100 (USNAS100.I) and S&P 500 (US500.I). US equity markets saw a very choppy session on Friday as interest-rate sensitive growth stocks dipped sharply on the strong July US jobs report. The broader market recovered most of the lost ground intra-day, but performance across themes was very mixed, with our Energy Storage basket the best performer among our “theme baskets”, likely on the passage of the climate bill by the US Senate (more below). Earnings season is winding down for the quarter, but a few prominent names are set to report this week, including Walt Disney on Wednesday.
KUALA LUMPUR, Malaysia , July 6, 2022 /PRNewswire/ -- Alcon Johor an affiliate of the largest eye care device company in the world with 75 years heritage, present in over 70 countries and serving patients in more than 140 countries by over 23,000 associates, has been recently recognized as one of the best places to work for in Malaysia for the second consecutive year. This acknowledges Alcon''s commitment towards fostering an environment and culture of respect, pride amongst its employees. According to the company results, 95% of the employees said it''s a great workplace compared to 79% in a typical company in Malaysia . It is a great feeling to be recognized as the Best Place to Work second year in a row. We are profoundly honored and humbled to receive this recognition; at Alcon, we are deliberate in creating a conducive environment that promotes our culture, where our associates are valued, recognized, and rewarded. We couldn''t have achieved this without the trust and belief of our associates.
JACKSONVILLE, Fla., June 23, 2022 /PRNewswire/ -- The following statement is being issued regarding In re Disposable Contact Lens Antitrust Litigation. Two class action settlements have been reached with Alcon Vision LLC f/k/a Alcon Laboratories, Inc. ("Alcon") and Johnson & Johnson…